Abstract: Zonisamide (ZNS) effi cacy and safety in epilepsy have been demonstrated in four double-blind, placebo-controlled studies. In the present article, we examined all long-term studies performed with this drug. Nine open-label studies, in which ZNS had been administered as an add-on or as monotherapy to epileptic patients for at least 6 months, were selected for our analysis. Four outcome measures were searched. Retention of this drug after 1 year varied between 45% and 65%. The percentages of patients achieving a Ն50% seizure reduction, with respect to baseline, ranged between 37% and 65%. In patients with drug-resistant forms of epilepsy, the percentage of patients reaching a 6-month seizure freedom period was 9%. The percentages of patients who discontinued the experimental drug due to adverse effects ranged between 4% and 24%. Somnolence and dizziness were the most frequently reported adverse effects. Long-term studies demonstrate that ZNS has a good effi cacy and tolerability profi le, and support its use as adjunctive therapy for epileptic patients.
Introduction
Zonisamide (ZNS) is a new antiepileptic drug (AED) that has been approved for broad use in Japan, while regulatory agencies in the USA and Europe have approved it only as an adjunctive therapy for treatment of partial seizures in adults.
This drug is a benzisoxazole derivative, fi rst synthesized in 1972, and is structurally different from all other AEDs. 1 Its anticonvulsant activity, which was fortuitously discovered, has been proven in a number of experimental seizure models. 1 Current evidence suggests that ZNS has multiple modes of action. It exerts its pharmacological effects by blockade of neuronal voltage-gated sodium channels and low-voltageactivated (T-type) calcium channels. 2 A modest inhibitory effect on carbonic anhydrase has been reported, which is thought to be 100 to 200 times less potent than that of acetazolamide. This mechanism is not believed to signifi cantly contribute to the antiepileptic actions of the drug. 3 ZNS has also some effects on the synthesis, release, and degradation of a number of different neurotransmitters, including glutamate, GABA, dopamine, serotonin, and acetylcholine which may lead to enhancement of synaptic inhibition. 4 Several in vitro experiments have shown that ZNS has some neuroprotective effects that may suggest a potential use in treating subjects with traumatic brain injury. 5 ZNS has a favorable pharmacokinetic profi le. It is rapidly absorbed from the gastrointestinal tract, and peak plasma concentrations are achieved within 2 to 5 hours after oral dosing. Food can reduce the rate, but not the extent, of absorption. Oral bioavailability approaches 100%, and the kinetics are linear after the administration of a single dose of 100 to 800 mg. 6 Although inactivation of ZNS occurs predominantly by hepatic metabolism involving CYP3A4-mediated reduction, this drug neither induces nor inhibits the hepatic cythochrome P450 isoenzymes that are implicated in the metabolism of several AEDs. 7 ZNS clearance increases to about 50% when administered in combination with other AEDs that are known inducers of CYP3A4, such as phenobarbital (PB), carbamazepine (CBZ), or phenytoin (PHT). However, since the half-life of ZNS is 50 to 70 hours in non-induced subjects, 8, 9 a slight increase of ZNS metabolism is not expected to have any signifi cant clinical effect. Nevertheless, if discontinuation of a co-administered, inducing AED is planned, the dose of ZNS should be adapted appropriately.
Finally, experimental data revealed only modest differences in the most relevant kinetic ZNS parameters between adults and special populations of young or old healthy volunteers. 9, 10 ZNS effi cacy and safety have been demonstrated in several pre-registration, randomized, double-blind, placebocontrolled studies in which this drug was administered as adjunctive therapy in drug-resistant epileptic patients. [11] [12] [13] [14] Results of these studies have been the object of several reviews and meta-analyses. 15, 16 The transferability of these fi ndings to clinical practice, however, is limited mainly because of the short duration of double-blind studies, which precludes any assessment of long-term effi cacy and chronic adverse effects. Furthermore, doses used in regulatory trials do not always refl ect those actually used in clinical practice, and the effi cacy and safety profi les of patients enrolled in randomized trials may differ strikingly from those of patients treated in the daily practice.
Several years ago, we compiled a review of the literature on long-term, open studies with gabapentin (GBP), lamotrigine (LTG), levetiracetam (LEV), and topiramate (TPM), when used as add-on in drug-resistant epileptic patients. 17 In that study, we searched for three robust markers of effi cacy or tolerability: the percentage of patients attaining a 6-month, seizure-free period; the percentage of patients withdrawing because of adverse effects; and the percentage of patients continuing treatment. Clear differences between these four drugs were observed.
Here, we analyze long-term studies performed with ZNS. The markers that we chose for this analysis were: the percentage of patients continuing treatment (retention in the study), the percentage of responder patients (those patients achieving a Ն50% seizure reduction), the percentage of patients attaining seizure freedom for a defi ned time (at least 6 months), and percentage of patients withdrawing from the study because of adverse effects. While the fi rst parameter is a mixed measure of effi cacy and tolerability, the second and third are pure measures of effi cacy, and the fourth is a pure measure of tolerability. The heterogeneity of the selected studies precluded any sophisticated analysis of the above-mentioned markers of effi cacy or tolerability.
Methods
In December 2008, a computer search of Medline (PubMed version) was conducted for all articles on ZNS using the following Boolean keyword syntax: zonisamide AND epilepsy. The Medline search produced 430 articles. Other studies were found by manual searching.
We found 41 open studies documenting the clinical evaluation of ZNS in epilepsy. From these articles we selected trials that met the following criteria: 1) open-label studies performed in epileptic patients to whom ZNS was administered as monotherapy or add-on therapy at standard dosages, 2) the duration of the study was at least 6 months, 3) at least one of the outcome measures (see below) had to be reported, 4) populations of adults and/or children were included. Studies specifi cally aimed at recruiting special populations (such as the elderly, intellectually disabled, patients affected by specifi c epileptic syndromes) were excluded.
Outcome measures
Our analysis included those trials that reported at least one of the following parameters: 1. Number and/or percentage of patients continuing the experimental treatment for the indicated period of time (6 months or longer). 2. Number and/or percentage of responders (a responder is a patient who has a Ն50% seizure reduction, with respect to a baseline seizure frequency). Although some studies reported the percentage of patients acquiring Ն25%, and Ն75% seizure reduction, for our analysis, we considered only the fi rst outcome measure. 3. Number and/or percentage of patients who were seizurefree for a specifi c period of time (at least 6 months). 4. Number and/or percentage of patients who withdrew from the study because of adverse effects.
Statistical analyses
The 95% confidence intervals (CI) were calculated to estimate the statistical variations of our end-points. Standard methods were used to calculate 95% CI of the mean. In the case of proportions, the calculation was based on the equations described by Fleiss.
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Results
Thirty-two studies were excluded from our analysis because they reported on specifi c epileptic syndromes of infancy, had insuffi cient or unspecifi ed durations, did not use our outcome measures for evaluation or for miscellaneous causes (such as duplication of data from other studies, utilization of unusual dosages, not published in English, French or Italian). Nine articles were selected for the analysis. [19] [20] [21] [22] [23] [24] [25] [26] [27] Their characteristics and results are summarized in Table 1 .
One of the chosen articles was a review 20 of long-term data from patients who had been recruited in the four key ZNS double-blind studies. [11] [12] [13] [14] From this review, we drew information concerning three extension studies (studies 922 ext, 912 ext, 912-39 ext, all conducted in US). In each study, the number of patients included in the open phase was reported. Data from the fourth long-term extension study included in Leppick's review has been recently published in extenso. 21 Therefore, for this study we selected data from the last publication only. While it was possible to report effi cacy data for any single extension study, the percentage of patients withdrawing for adverse effects was available only as cumulative data from all of the double-blind, and some open, long-term studies. 20 We considered each of these evaluations as a separate study. Therefore, the total number of clinical studies actually included in our analysis was 12. Nine studies were prospective, [19] [20] [21] [22] [23] 26 and three were retrospective. 24, 25, 27 The main difference among the selected studies was the population of patients recruited. The first group of eight studies [19] [20] [21] [22] [23] was performed in adult, drug-resistant patients, mainly with localization-related epilepsies, and in whom ZNS was added to a previous AED treatment. Two retrospective studies included patients treated with ZNS as monotherapy. 24, 25 However, in both studies, the patient population was heterogeneous, consisting of newly diagnosed patients and patients who were being treated with another AED that was later withdrawn due to its ineffectiveness or lack of tolerance.
One prospective study 26 included a mixed population of pediatric patients treated with ZNS, as an add-on or monotherapy. Finally, the last study was retrospective, and the percentage of patients on monotherapy or polytherapy was not specifi ed. 27 
Retention of patients in the trial
Five of the studies provided this information, [19] [20] [21] [22] 24, 27 and these data, calculated at different time points, are reported in Figure 1 . In all of these studies, ZNS was added in lieu of an unsatisfactory AED treatment. We observed that the percentages of patients who continued to use this drug after 1 year ranged between 50% and 60%, with a modest dropoff over time.
Percentage of responders
The percentages of patients achieving a Ն50% seizure reduction, with respect to a baseline seizure frequency, was calculated for each of the seven studies, 20, 21, 23, 24, 26 and is represented in Figure 2 . We observed that, in those studies where ZNS was added to a previous therapy, 20, 21, 23 percentages of responders were between 37% and 50%. In those studies performed on mixed populations of patients 24, 26 (patients mainly on monotherapy with presumably less severe forms of epilepsy), percentages of responders were higher (between 60% and 65%).
Patients who were seizure-free
The percentage of patients reaching seizure freedom was given in three studies. 21, 24, 25 However, one study calculated this parameter in a manner that was different to the other two. The fi rst study, 21 conducted on a population of drug-resistant patients, considered those patients who did not have seizures for a period of 6 or 12 months during the study, and at the end of the observation period (terminal seizure freedom) ( Table 1) . The two remaining studies, 24, 25 in which ZNS was given as a monotherapy, considered those patients who had been free of seizures for at least 6 months, to be 6-months seizure-free.
Patients who discontinued the study due to adverse effects
The percentage of patients who discontinued the experimental drug because of adverse effects were reported in seven clinical studies 19, 20, [22] [23] [24] [25] 27 and were between 4% and 25% (see Figure 3 ). It was evident that these seven studies, which were long-term extensions of double-blind studies, had dropout rates that were generally higher than prospectiveopen studies.
Discussion
Effi cacy and tolerability of ZNS have been demonstrated in four double-blind, placebo-controlled, multicenter trials. [11] [12] [13] [14] In these studies, about 800 patients with drug-resistant forms of epilepsy received ZNS for a period of Յ6 months. The overall results of these studies showed that ZNS was effective at doses of 300 to 500 mg/day, although it was suggested that lower doses may be benefi cial for some patients. 28 Treatment-related adverse events were mostly mild to moderate in severity and resulted in few discontinuations. In fact, only 19.3% of patients withdrew due to adverse side effects, compared with 8.6% of placebo-treated patients. 
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However, the transferability of fi ndings obtained from these double-blind studies to clinical practice, is limited by several factors. First, the doses used did not refl ect the actual ones used in clinical practice. For example, in two studies, ZNS doses were fi xed and some patients were randomized to a dose, which were ineffective. 11 This may have led to an apparently low overall effi cacy. 16 Second, the effi cacy and safety profi les in patients enrolled in randomized trials may differ from those of patients treated in everyday practice. Finally, the follow up period of these double-blind studies was short, being Յ6 months.
Since epilepsy is a chronic disease, in the majority of cases AEDs must be taken for years and often for the life of a patient; thus, further studies are necessary to ascertain whether a treatment will maintain its effi cacy and tolerability over the long-term.
The analysis of long-term, open-label studies is a useful way to provide this crucial information.
In our review, we included studies performed in different populations of patients. It has been reported that the range of patients with newly diagnosed epilepsies and whose seizures are completely controlled by a fi rst AED, is 50% to 60%. In those patients who continue to have seizures despite multiple, appropriate drug treatments, the chance of becoming seizure-free when a new AED is added is lower than 5%. 29 For this reason, clinical data from add-on studies must be discussed apart from those where this drug was used as monotherapy.
Long-term, add-on, studies performed in patients with drug-resistant epilepsies
These studies were all prospective and were often open, long-term extension studies of previous double-blind studies. 20, 21 Three studies 19, 22, 23 were not extensions of controlled studies, but were each performed in similar populations of drugresistant patients. A retrospective study was performed, at least in part, in a presumably similar population of patients. 27 Retention data, available only for some of these studies, 19, 21, 22, 27 showed that the percentages of patients continuing treatment with the experimental drug after 1 year were between 60% and 70%, with only a modest decrease over time. Data from other AEDs, 17 in similar populations of patients, showed that after 1 year, retention of GBP was very low, at 25%, while LTG had retention values between 40% and 60%, TPM retention was around 55%, and LEV, which had the best scores, had retention values between 60% 
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Politherapy studies Politherapy studies Polytherapy studies Monotherapy studies and 80%. Therefore ZNS, in regard to this mixed measure of effi cacy and tolerability, had a performance similar to that of most effective AEDs. The purest measure of effi cacy is the percentage of patients who reached a seizure-free state for a certain period of time. In a previous analysis, 17 we considered those patients who did not have seizures for 6 months to be seizure-free; this evaluation, was reported in three studies (Table 1) . 21, 24, 25 One of these studies, however, included a population of patients who were not controlled with the appropriate AED treatment. In this study, 21 about 9% of patients acquired a 6-month period of seizure freedom, but only 2% of patients were seizure-free in the last 6 months (terminal seizure freedom). Data obtained from a study of other AEDs, 17 reported that GBP and LTG were associated with 6-month seizure-freedom rates below 4%, while TPM had seizurefree rates around 8% and LEV about 13%. However, the method used for calculating seizure freedom may infl uence the result. In fact, as the duration of a study increases, so does the probability of acquiring seizure freedom for the specifi ed period of 6 months; and the probability of attaining terminal 6-month seizure freedom is stable.
In this review we have also considered another, less robust, measure of effi cacy: percentage of patients achieving a reduction in seizure frequency of Ն50%, with respect to baseline. Findings from studies on drug-resistant patients who reported this outcome measure 20, 21, 23 ( Figure 2 ) to be between 35% and 50%, allowed comparison with doubleblind studies where similar parameters were evaluated. In a review of all double-blind studies, 28 similar values were observed when patients were randomized to a ZNS dose of 300 to 500 mg/day. This fi nding confi rmed data from controlled studies and indicated that ZNS maintained its effi cacy over time.
With regards to tolerability in populations of patients with drug-resistant epilepsies, we found ( Figure 3 ) that in some studies, 19, 20, 22, 23, 27 the percentage of patients withdrawing from the experimental drug was around 25%, while other studies reported lower percentages. We can speculate that, at least in some cases, this difference may be a consequence of the titration scheme. In fact, the long-term studies which were extensions of previous double-blind studies 20 (in doubleblind studies a fi xed-titration scheme and a high maintenance dose has to be reached) had higher withdrawal rates than those studies in which a low standard initial dose was used, and where titration speed and fi nal doses were individually adjusted. In two of these studies, 22, 23 fewer than 10% of patients withdrew because of adverse effects. Similar studies performed with other AEDs found percentages around 28% for TPM, and lower for GBP, LTG and LEV (18%, 15%, and 13% respectively). 17 Long-term studies performed in patients on monotherapy
Data about effi cacy and tolerability of ZNS administered as monotherapy was derived from four studies. Due to heterogeneity of patients recruited and treatment administered, only some of the data could be used in our study. Two retrospective studies 24, 25 included patients with newly diagnosed epilepsies and patients who discontinued treatment with a previously unsatisfactory AED (for ineffi cacy or lack of tolerability). It was reported that the percentage of patients with newly diagnosed epilepsies, whose seizures were completely controlled by the fi rst AED used, ranged between 50% and 60%.When the fi rst AED was ineffective, the chance of a second AED being fully effective was about 10%. 29, 30 Two other studies 26, 27 included patients treated with ZNS as an add-on and monotherapy. The studies did not provide separate analyses.
Data about retention was reported in one study only. 27 This included patients on both monotherapy and polytherapy, with unknown percentages, and was a retrospective monotherapy study. Results, already discussed in the previous section, did not give information on ZNS effectiveness when this drug was administered as a monotherapy. The percentage of patients on monotherapy who acquired seizure freedom for at least 6 months was reported in two studies. 24, 25 In both cases, they (between 24% and 26%) were higher than that usually observed in drug-resistant patients, but much lower than that found when a new drug was administered to newly diagnosed patients. 29, 30 The result probably refl ects the heterogeneity of the studied population.
Responder rates were calculated in two studies 24, 26 and ranged between 60% and 65%. This, too, may refl ect the heterogeneity of the populations included in these studies. Finally, the percentage of patients withdrawing because of adverse effects was low in both monotherapy studies, 24, 25 but was higher in one study with a mixed population of patients on add-on or monotherapy ZNS treatment. The limited amount, and the heterogeneity, of data did not allow us to draw defi nitive conclusions on effi cacy and tolerability of ZNS administered as monotherapy.
Long-term adverse effects of zonisamide
From the analysis of double-blind controlled studies emerges a favorable ZNS tolerability profi le. 16 In a meta-analysis
Long-term zonisamide use in epilepsy of all adverse effects observed with new AEDs in key, placebo-controlled clinical studies, ZNS and GBP signifi cantly associated with two adverse effects (somnolence and dizziness), while LEV associated with one adverse effect; all other AEDs signifi cantly associated with three or four adverse effects. 31 In Table 2 , the adverse effects most frequently observed in some long-term studies are reported. 19, 20, 21, 22 Somnolence and dizziness were the most frequently observed adverse effects.
Adverse effects characteristic of ZNS and TPM, included anorexia and/or decreased appetite. These effects generally caused a small amount of weight loss, which did not appear to be progressive and stabilized over period of 2 years. 20 In some controlled studies, 12,13 a small percentage of patients developed cognitive problems during short-term ZNS treatment. Table 2 shows that adverse effects were also observed during longterm treatment. These effects were usually related to dose and titration speed. 20, 32 To specifi cally address long-term effects of different doses of ZNS on cognition, an assessment of several cognitive functions was performed in epileptic patients before, and after 1 year of ZNS treatment. It was observed that some cognitive functions, such as delayed word recall and verbal fl uency, were adversely affected by ZNS after 1 year of treatment, and that the effect was more pronounced at higher doses. 33 Kidney stones, a relatively rare complication of ZNS, were reported in about 4% of chronically treated patients. 34 In Leppik's study, 19 which is the oldest long-term study, kidney stones were observed in 3.5% of their patients. Other less frequently reported, and often idiosyncratic, adverse effects do not always emerge from the analysis of clinical studies. Oligohydrosis was reported in one study only, 22 and may be rarely caused by ZNS. 1, 5, 8 The suggested mechanism may be the weak inhibition of carbonic anhydrase by ZNS. In a small percentage of cases (between 1.4% in USA and Europe, and 2% in Japan), a cutaneous rash, leading to drug discontinuation, was associated with ZNS treatment. Interestingly, this rash was more frequently observed in patients on monotherapy than in patients on polytherapy. 8, 35 . Low incidences of serious skin reactions, such as StevensJohnson syndrome and toxic epidermal necrolysis, have been reported by post-marketing experiences from Japan. 20, 36 In conclusion, ZNS is a new AED, which has been approved in the USA and Europe as adjunctive therapy for epileptic patients who are refractory to monotherapy. Among all other new AEDs which have been approved for this indication, ZNS should be considered because it has a predictable pharmacokinetic profi le, allowing once-or twicedaily dosing, and no clinically relevant interactions with other fi rst-line AEDs. Also, this drug has multiple mechanisms of action, which beget two important advantages: a broad spectrum of action in the fi eld of epilepsy and possible effects on other neurological or psychiatric diseases. Uncontrolled data suggest that benefi cial effects extend across a range of seizure types and syndromes including generalized epilepsy, 37 juvenile myoclonic epilepsy, and progressive myoclonic epilepsy. 36 ZNS is also under evaluation for the treatment of several other diseases. To date, controlled studies have shown that at doses of 25 to 100 mg/day, it is an effective adjunctive treatment in patients with Parkinson disease.
38 ZNS is also being tested for treatment of essential tremors. 39, 40 Since ZNS, like TPM, is associated with weight loss, trials have also been performed in obese patients 41 and patients with binge eating disorder, with interesting results. 42, 43 Preliminary data suggest that ZNS may be effective for prophylactic treatment in patients with bipolar disorders. 44 Finally, one open study showed that this drug may be a safe and effective adjunctive agent for migraine prevention, 45 while one controlled study failed to show clinically signifi cant results in patients with painful, diabetic neuropathies. 46 Epilepsy is a chronic condition that may be associated with several other diseases. 47 In patients who display other diseases in association with epilepsy, the availability of a drug that exerts a positive effect on the comorbid disease may be of strategic importance for optimizing therapy on an individual basis. 48 Our review of long-term studies shows that ZNS maintains its effi cacy and has good tolerability over time. It may therefore be a good choice as an add-on treatment in epileptic patients where other AEDs have produced unsatisfactory results.
Disclosures
The authors disclose no confl icts of interest.
